This study evaluates dalbavancin, an antibiotic with a long duration of action, in treating complex bone and joint infections. It does not require daily dosing, allowing patients to leave the hospital earlier and reducing costs. Dalbavancin is shown to be effective and safe, especially for patients unsuitable for oral antibiotics or outpatient therapy, achieving similar results to traditional treatments while cutting healthcare costs.

We explore optimising antibiotic use to prevent infections in endoprosthetic replacement for bone tumours. We found 26 % of infections were linked to initial surgery, with most due to secondary factors like wound complications. The main bacteria are Staphylococcus aureus and coagulase-negative staphylococci. Our findings suggest targeting these bacteria with prophylactic antibiotics and applying measures to prevent secondary infections to improve infection control in orthopaedic oncology.

Our orthopaedic hospital attempts to culture tuberculosis (TB) bacteria from all bone and joint samples sent to the microbiology laboratory. We looked at 6162 TB cultures performed between 2017 and 2022. Bacteria that cause TB, or similar bacteria, were found in 1 in every 229 patients. Tests were more likely to be positive in people being investigated for cancer (sarcoma) and in samples from the spine, whereas they were much less likely to be positive in samples taken from replacement joints.

We present the first reported case of prosthetic joint infection caused by Trueperella pyogenes. This animal pathogen rarely causes human infection. Our patient was successfully treated with single-stage exchange and 12 weeks of rifampicin and moxifloxacin.